Ronald A. Fleming - Concepedia

Author

Ronald A. Fleming

Also Known As

Fleming, Ron, Fleming, Ronald A., R A Fleming, R FLEMING, R Fleming, R. A. Fleming, R. Fleming, R.A. Fleming, Ronald A Fleming, Ronald A. Fleming

117

Publications

4.4K

Citations

H-Index

133

Concepts

All Affiliations

Wake Forest University GlaxoSmithKline (United States)Research Triangle Park Foundation University of Tennessee Health Science Center University of Kentucky

About

Ronald A. Fleming is an author at Wake Forest University specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	27	2.4K
2	Engineering	9	9	553
3	Natural Sciences	3	3	257
4	Business	2	2	156
5	Health Sciences	2	2	228

Ronald A. Fleming

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
Population study of dihydropyrimidine dehydrogenase in cancer patients. M C Etienne, J.-L. Lagrange, O. Dassonville, Journal of Clinical Oncology	1994	431
Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy With Mitomycin C for Peritoneal Carcinomatosis from Nonappendiceal Colorectal Carcinoma Perry Shen, Jason Hawksworth, James Lovato, Annals of Surgical Oncology Cytoreductive SurgeryIntraperitoneal Hyperthermic ChemotherapySurgical OncologyMitomycin CColorectal Surgery	2004	278
Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Ronald A. Fleming, G. Milano, Antoine Thyss, PubMed PathologyPharmacotherapyCancer PatientsOncologyPlasma Uracil Concentrations	1992	235
A reassessment of the economic effects of global climate change on U.S. agriculture Richard M. Adams, Ronald A. Fleming, Ching-Chang Chang, Climatic Change Agricultural ImpactAgricultural ResilienceEnvironmental ImpactsEngineeringEconomic Effects	1995	229
An Overview of Cyclophosphamide and Ifosfamide Pharmacology Ronald A. Fleming Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy Ifosfamide OccursAntiparasitic AgentPharmacotherapyPharmaceutical ChemistryToxicological Mechanism	1997	195
Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis Richard P. McQuellon, Brian W. Loggie, Ronald A. Fleming, European Journal of Surgical Oncology Intraperitoneal Hyperthermic ChemotherapySurgical OncologyPeritoneal CarcinomatosisMedicineCancer Management	2001	163
Long-Term Survivorship and Quality of Life After Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis Richard P. McQuellon, Brian W. Loggie, Anna B. Lehman, Annals of Surgical Oncology Surgical OncologyPeritoneal CarcinomatosisMedicineCancer ManagementLong-term Survivorship	2003	157
Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Disseminated Peritoneal Cancer of Gastrointestinal Origin Brian W. Loggie, Ronald A. Fleming, Richard P. McQuellon, The American Surgeon Cytoreductive SurgeryIntraperitoneal Hyperthermic ChemotherapySurgical OncologyGastric OriginsGastrointestinal Oncology	2000	155
The Uniform Approach to Breast Fine Needle Aspiration Biopsy Marluce Bibbo, Andrea Abati, Alex Ferenczy, Acta Cytologica Medical ImagingUniform ApproachCancer DetectionBiomedical ImagingHistopathology	1996	145
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors Jean‐Charles Soria, Hui Gan, Sarah P. Blagden, Annals of Oncology Pharmacodynamic StudyMedicineCell AdhesionReceptor Tyrosine KinasePharmacology	2016	140

Page 1